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ABSTRACT
Objectives: Our objective was to compare the efficacy and safety of three drug combinations
for the treatment of late-stage human African trypanosomiasis caused by Trypanosoma brucei
gambiense.
Design: This trial was a randomized, open-label, active control, parallel clinical trial comparing
three arms.
Setting: The study took place at the Sleeping Sickness Treatment Center run by Me ´decins
Sans Frontie `res at Omugo, Arua District, Uganda
Participants: Stage 2 patients diagnosed in Northern Uganda were screened for inclusion and
a total of 54 selected.
Interventions: Three drug combinations were given to randomly assigned patients:
melarsoprol-nifurtimox (MþN), melarsoprol-eflornithine (MþE), and nifurtimox-eflornithine
(NþE). Dosages were uniform: intravenous (IV) melarsoprol 1.8 mg/kg/d, daily for 10 d; IV
eflornithine 400 mg/kg/d, every 6 h for 7 d; oral nifurtimox 15 (adults) or 20 (children ,15 y)
mg/kg/d, every 8 h for 10 d. Patients were followed up for 24 mo.
Outcome Measures: Outcomes were cure rates and adverse events attributable to
treatment.
Results: Randomization was performed on 54 patients before enrollment was suspended due
to unacceptable toxicity in one of the three arms. Cure rates obtained with the intention to
treat analysis were MþN 44.4%, MþE 78.9%, and NþE 94.1%, and were significantly higher with
NþE( p¼0.003) and MþE( p¼0.045) than with MþN. Adverse events were less frequent and less
severe with NþE, resulting in fewer treatment interruptions and no fatalities. Four patients died
who were taking melarsoprol-nifurtimox and one who was taking melarsoprol-eflornithine.
Conclusions: The NþE combination appears to be a promising first-line therapy that may
improve treatment of sleeping sickness, although the results from this interrupted study do not
permit conclusive interpretations. Larger studies are needed to continue the evaluation of this
drug combination in the treatment of T. b. gambiense sleeping sickness.
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PLoS CLINICAL TRIALSINTRODUCTION
Human African trypanosomiasis (HAT) or sleeping sickness,
caused by the protozoan parasite Trypanosoma brucei gambiense
transmitted by the Tsetse ﬂy (Glossina spp.), progresses from
the hemolymphatic phase (stage 1) to the meningoencepha-
litic phase (stage 2). Without appropriate treatment, the
disease is invariably fatal. Since 1949, melarsoprol has been
the most commonly used stage 2 treatment. This arsenical
derivative is associated with severe toxic effects, in particular
a reactive encephalopathy that is fatal in 10%–70% of cases
and affects 5%–10% of patients treated [1,2]. An additional
concern is the increase of melarsoprol treatment failures
reported in several countries, up to 30% [3–5].
Eﬂornithine or DFMO (diethylﬂuoromethylornitihine),
initially evaluated for the treatment of cancer, has been the
only new drug registered in over ﬁve decades for HAT. Better
tolerated than melarsoprol, its toxic effects—mainly seizures,
gastrointestinal disorders, and myelosuppression—are rever-
sible if well managed. Its efﬁcacy is comparable to that of
melarsoprol in areas without melarsoprol-refractory HAT.
However, a major disadvantage of eﬂornithine is the
complicated mode of administration requiring one slow
infusion every six hours for 14 days (56 infusions in total).
Nifurtimox, an inexpensive, orally administered drug used
in the treatment of Chagas’ disease (caused by T. cruzi), is not
registered for HAT but it is nevertheless used for compas-
sionate treatment. Its toxicity is poorly documented, but
appears to cause mainly neurological and gastrointestinal
disorders that increase with the duration of intake. It was
tested empirically in HAT case series during the 1970s and
1980s with conﬂicting results [6–9]. These evaluations
differed in treatment regimens and evaluation criteria,
making them difﬁcult to compare.
Currently no new drugs for stage 2 HAT are in clinical
development, meaning that new treatments for this condition
are unlikely to be available in the next decade. It has become
urgent, therefore, to explore new therapeutic alternatives.
Drug combinations have the potential to protect the two
partner drugs against selection of resistant strains, thus
delaying the emergence of drug-resistant organisms. Combi-
nations may allow dosage reduction of each drug in the
combination, reduce the overall toxicity while maintaining
good efﬁcacy. Combinations may also allow for a simpler
administration, improving the feasibility of treatment in
Africa’s isolated health facilities, most of which have logistic
and stafﬁng limitations.
In 2001, Me ´decins Sans Frontie `res (MSF; Paris, France) and
Epicentre (Paris, France), in collaboration with the Ugandan
Ministry of Health, initiated a clinical trial to evaluate the
efﬁcacy and toxicity of three drug combinations with doses
smaller than those used in monotherapy.
METHODS
We followed closely the methods of previous clinical trials
with second-stage trypanosomiasis patients [10–12] to facil-
itate external comparability. The trial was implemented at
the MSF HAT treatment center in Omugo, Arua district,
Uganda.
Participants
Potential participants were identiﬁed among cases routinely
diagnosed at the center or during active screening campaigns.
Ultimately 54 (27 men and 27 women, age range 5–62 y) were
included in the study. Inclusion criteria were: conﬁrmed
second-stage T. b. gambiense infection with trypanosomes
detected in the cerebrospinal ﬂuid (CSF) with any CSF
leukocyte count, or trypanosomes detected in blood or lymph
node ﬂuid with more than ﬁve leukocytes per microliter in
CSF. Exclusion criteria were: body weight under 10 kg,
pregnancy, history of stage 2 HAT treated during the
preceding 24 months, or unlikelihood of completing the
two-year follow-up.
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Editorial Commentary
Background: African trypanosomiasis, or sleeping sickness, is a serious
illness that is thought to affect many tens of thousands of people each
year in sub-Saharan Africa. The disease is caused by a single-celled
parasite that is transmitted to people when they are bitten by an
infected Tsetse fly. If the initial phase of the disease is not recognized
and treated, the parasite infects the brain, resulting in confusion, sleep
problems, and ultimately coma and death. Few treatment options exist,
and the most commonly used drug, melarsoprol, is highly toxic;
furthermore, parasites are evolving resistance to it in some regions.
There is an urgent need to develop new drugs and to evaluate
combinations of existing drugs for activity against African trypanoso-
miasis. Therefore a group of researchers from Epicentre, Me ´decins Sans
Frontie `res, and the National Sleeping Sickness Control Programme in
Uganda performed a trial evaluating the efficacy and safety of three drug
combinations. The combinations compared were melarsoprol-nifurti-
mox, melarsoprol-eflornithine, and nifurtimox-eflornithine, and the
researchers planned to recruit 435 people with second-stage African
trypanosomiasis in Uganda who would be followed up for 24 months.
The primary outcome for the trial was cure rate following treatment.
However, once 54 patients had been recruited into the trial, it was
obvious that the death rate was much higher among individuals
receiving melarsoprol-nifurtimox; the trial was therefore stopped for
ethical reasons and this paper reports the results obtained up to that
point.
What this trial shows: At follow-up, the cure rate observed for the
nifurtimox-eflornithine combination was over twice that for melarsoprol-
nifurtimox and substantially higher than that for melarsoprol-eflorni-
thine. Although the number of participants recruited into the trial was
much lower than originally planned, the differences in cure rates
between nifurtimox-eflornithine and the other two treatments were
statistically significant. Deaths and serious adverse events were much
more common among patients receiving melarsoprol-nifurtimox than
the other two combination therapies.
Strengths and limitations: Trials evaluating treatments for African
trypanosomiasis are very rare, and properly randomized studies such as
this one provide important data on the efficacy and safety of different
treatments. A high proportion of individuals recruited into the trial were
followed up for the full two years, and the primary outcome of the trial—
the cure rate—was appropriate. A key limitation of the study is that the
trial was terminated early; therefore, the differences in efficacy observed
in this trial should not be seen as definitive.
Contribution to the evidence: The results from this trial suggest that
the nifurtimox-eflornithine combination has potential as a future therapy
for stage 2 African trypanosomiasis, and should be evaluated further in
clinical trials. Very little other data currently exist on the efficacy and
safety of this drug combination.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.The study protocol was approved by the Uganda National
Council for Science and Technology, the ofﬁcial research
ethics committee in Uganda. All participants gave written
informed consent.
Interventions
Participants were randomized into three arms: melarsoprol-
nifurtimox (MþN), melarsoprol-eﬂornithine (MþE), and ni-
furtimox-eﬂornithine (NþE).
The dosages were established by the study Scientiﬁc
Committee (an ad-hoc group of international experts
coordinated by Epicentre, Paris), on the basis of the existing
published and unpublished data. The dosage of each drug was
the same in all arms: melarsoprol 1.8 mg/kg/d in direct
intravenous (IV) injection, once daily for 10 d; eﬂornithine
400 mg/kg/d in slow IV infusion, every 6 h for 7 d; nifurtimox
15 (adults) or 20 (children ,15 y) mg/kg/d in tablets taken
orally, every 8 h for 10 d. Each eﬂornithine dose was infused
over 2 h, diluted in 250 ml of normal saline. Nifurtimox doses
were repeated if vomiting occurred within 30 min. All doses
were administered by the medical staff, and tablet intake was
directly observed.
Two days before commencing the treatment, all patients
were pretreated with albendazole (400 mg single dose), those
with malaria parasites (conﬁrmed by microscopy and rapid
diagnostic test) received single-dose sulfadoxine-pyrimeth-
amine, and those with microﬁlariae (conﬁrmed by micro-
scopy) received single-dose ivermectin (3–12 mg according to
height) unless contraindicated. Treating microﬁlariae was
routine practice aimed at preventing encephalopathy. Pa-
tients on melarsoprol received concomitant oral predniso-
lone 1 mg/kg/d for 5 d, and 0.5 mg/kg/d until treatment
completion, a currently accepted routine practice aimed at
reducing the risk of encephalopathy. Patients and attendants
received a food ration of at least 2,100 kcal/d each.
All patients were medically assessed daily, and hospitalized
until one day after the end of treatment, or longer if judged
necessary by the clinicians to ensure the patient’s welfare.
Parasitological lab examinations, including lumbar puncture,
blood exams, and lymph node puncture, were performed on
the day following the last dose and at 6, 12, and 24 mo. At
each laboratory control the CSF was examined for parasites
by double centrifugation and a parallel CSF leukocyte count
was performed. Blood was examined by capillary tube
centrifugation and QBC (quantitative buffy coat) techniques.
Lymph node ﬂuid was examined from any palpable posterior
cervical lymph node.
A diagnosis of relapse was made if, at any time after
termination of treatment, trypanosomes were seen in any
body ﬂuid or if the CSF leukocyte count was 20 or more per
microliter and was either higher than at the end of treatment
or had increased twice consecutively. When a single increase
was detected, patients were examined again three months
later. At the 24-month examination, a diagnosis of relapse
was made if the CSF leukocyte count was 20 or more per
microliter, regardless of previous counts. No distinction was
made between disease recurrence and relapse, since it is not
possible to distinguish relapse from reinfection, and the
disease transmission in the area had been substantially
reduced after seven years of intensive control activities by
MSF.
Safety was assessed following the international Common
Toxicity Criteria guidelines [13], which grade adverse events
by intensity from 1 to 4 (mild, moderate, severe, or very
severe), drug-event relationship (unlikely, possible, probable,
deﬁnite, or unknown), and outcome (complete recovery, still
present, sequelae, or death). A subgroup of patients had a
blood sample taken before and after treatment, examined for
hemoglobin, total and differential leukocyte counts, and
thrombocytes. Anemia was deﬁned as hemoglobin ,13 g/dl
(male) and ,11 g/dl (female); leukopenia as ,4,000 leuko-
cytes/ll; neutropenia as ,2,000 neutrophils/ll; and thrombo-
cytopenia as ,100,000 thrombocytes/ll.
Objectives
The objectives of the study were to evaluate the efﬁcacy and
toxicity of three drug combinations for late-stage gambiense
HAT.
Outcomes
The primary outcome was the cure rate. The following
endpoints were regarded as therapeutic failures: (1) deaths in
temporal relation to treatment (within 30 days of treatment
start) and (2) relapses of HAT or death compatible with HAT
within the 24 months of follow-up. All deaths due to disease
without clearly established alternative causality were re-
garded as compatible with HAT. Secondary outcomes were
the adverse events temporally associated with the treatment,
in particular the major adverse events: severe (grade 3) and
very severe (grade 4).
Sample Size
The sample size originally had been set at 145 patients per
arm (435 in total), to test equivalence in cure rates at 24
months, but early interruption of recruitment (see below)
rendered the equivalence analysis impossible.
Randomization—Sequence Generation
The randomization list in blocks of 18 was electronically
generated at Epicentre headquarters in France, using a
Microsoft Excel macro designed with Visual Basic scripting.
The ﬁeld team that enrolled and allocated treatments had no
participation in this task.
Randomization—Allocation Concealment
The randomization list and the block size were concealed
from the ﬁeld team. Sealed and numbered opaque envelopes
contained the treatment allocation.
Randomization—Implementation
Participants were enrolled in the same order in which they
were diagnosed. The sealed envelopes were opened in strict
numeric sequence.
Blinding
Blinding was not feasible due to the very different admin-
istration modes of the drugs.
Statistical Methods
Data were collected in speciﬁcally designed patient charts,
double-entered electronically with EpiData version 3.0 (The
EpiData Association, Odense, Denmark), and analyzed with
EpiInfo version 6.04b (Centers for Disease Control, Atlanta,
Georgia, United States) and Stata version 8.2 (StataCorp,
College Station, Texas, United States).
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the Fisher’s exact test. Because of the small sample size,
adverse events are reported in tabular form without statistical
comparisons.
RESULTS
Participant Flow
Of 292 HAT cases diagnosed during the trial period, 104 were
at stage 2, of whom 54 responded to the entry criteria and
were enrolled in the study (Figure 1). The main reason for
ineligibility was impossibility of follow-up (i.e., patients
referred from Southern Sudan). One patient allocated to
MþE group died before treatment initiation. Thus, 53
patients were treated: 18 with MþN, 18 with MþE, and 17
with NþE.
Recruitment
The enrollment started in March 2001 and was suspended by
the investigators in November 2001 for ethical reasons due to
the high fatality observed in the MþN arm and the strong
contrast of overall toxicity per arm. The nonblinded nature
of our trial made the observation of higher-than-expected
fatality in one arm unavoidable. MþN deaths were caused by
acute reactive encephalopathy: given the nature of this risk (a
sudden-onset, highly fatal event that, once it has occurred
cannot be mitigated by treatment interruption and patient
withdrawal), there was no other choice but to interrupt the
trial. Enrollment was not resumed and was deﬁnitively
terminated in March 2002, when Uganda changed its regional
ﬁrst-line treatment from melarsoprol to the less-toxic
eﬂornithine, further compromising the ethical justiﬁcation
for continuing a trial using treatments that are more toxic
than the new routine therapy. The option chosen at that
point was to organize a new study in which patients were to
receive only the safest of the three combinations.
Baseline Data
The baseline characteristics were similar in the three groups
(Table 1). Nonsigniﬁcant but noteworthy differences were: a
higher number of patients with detected CSF parasites and
with high CSF leukocytes counts in the MþE arm; fewer
patients with high CSF leukocytes counts in the NþE arm.
Numbers Analyzed
We conducted an intention-to-treat analysis on the full
dataset of randomized patients (n ¼ 54). All-cause mortality
during treatment or follow-up was regarded as failure. For
the partially followed up and still alive patients, the last valid
observation was carried forward.
In the per-protocol analysis (n¼53), one patient (allocated
to the MþE arm) was excluded because he died before
treatment initiation. As planned in the protocol, deaths
during follow-up were not regarded as failures if the cause
was unrelated to HAT. In those cases, the last valid
observation was carried forward.
Figure 1. Trial Profile
Footnotes are as follows.
aOral report of death compatible with HAT.
bControlled at 14 mo: favorable evolution, died later during uterus surgery.
cControlled at 6
and 15 mo, respectively: favorable evolution, both moved away later.
dControlled at 6 mo: favorable evolution, died later of snake bite.
doi:10.1371/journal.pctr.0010039.g001
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case scenario’’ (n¼54), in which all relapses, all fatalities, and
all incomplete follow-ups were regarded as failures.
In the safety analysis all 53 patients receiving treatment
were included.
Outcomes and Estimation
One patient died before treatment initiation. Five patients
died in temporal relation to treatment and were considered
treatment failures. Of the remaining 47 patients followed up
after treatment, the majority (43/47 [91.5%]) completed the
follow-up per protocol, and the rest (4/47 [8.5%]) had at least
one control done (range 6–15 mo). Of these partially followed
up patients, one died during surgery, one died of snakebite
poisoning, and two moved away after being controlled at 6
and 15 mo, respectively. At their last controls, the four had
shown a favorable evolution.
By intention-to-treat analysis, cure rates were 44.4% for
MþN, 78.9% for MþE, and 94.1% for NþE A signiﬁcant
advantage compared to MþN was found for NþE( p ¼ 0.003)
and MþE( p ¼ 0.045) (Table 2).
The per-protocol analysis and the ‘‘worst-case scenario’’
sensitivity analysis support the signiﬁcant advantage of the
NþE( p ¼ 0.001 and 0.003, respectively) combination over
MþN, but not that of MþE( p ¼ 0.075 and 0.191, respectively).
Adverse Events
Among the ﬁve patients who died within 30 d (range 2–19 d)
of the start of treatment, four (22.2%) received MþN and one
(5.9%) MþE; no deaths occurred with NþE. The four deaths
with MþN were attributed to reactive encephalopathy, two of
them occurring at home after discharge. The death under
MþE was attributed to severe colitis and dehydration.
The difference in major adverse events (grades 3 and 4)
between MþN( n ¼ 18) and MþE( n ¼ 9) and NþE( n ¼ 5)
presents a strong contrast, although the small number of
observations precludes a demonstration of signiﬁcance
(Table 3). There were 12 treatment interruptions, including
three deﬁnitive halts due to severe adverse events under MþN
and nine suspensions, four in each of the melarsoprol-
combination arms plus one in the NþE arm. These inter-
ruptions were most often due to seizures (n ¼ 5) and/or
combinations of headache (n ¼ 4), fever (n ¼ 3), coma,
agitation, confusion, tremor, dizziness, diarrhea, arrhythmia,
hypertension and pruritus (n ¼ 1 each). The ﬁve major
adverse events observed with NþE were seizures (n ¼ 4) and
neutropenia (n ¼ 1), all of which resolved favorably.
Before-and-after hematological results were available for
37 (hemoglobin), 36 (leukocytes), and 15 (thrombocytes)
patients. Two patients (one MþE and one NþE) developed
grade 3 neutropenia (,1,000 neutrophils/ll). One developed
mild anemia (MþE). None developed thrombocytopenia.
Only two patients had received ivermectin prior to the
study drugs, both in the NþE arm. One (receiving 12 mg) had
no signiﬁcant adverse events, and the other (receiving 9 mg)
had one episode of convulsions 11 days after taking the
ivermectin.
DISCUSSION
Interpretation
A comparison of cure rates, which was the primary outcome
of the study, shows a signiﬁcant advantage of the NþE over
the MþN combination. This analysis was done on a sample
size much smaller than planned, due to the early interruption
of enrollment.
For the efﬁcacy evaluation we obtained an excellent rate of
follow-up, considering that 100% of followed patients had at
least one control done and that 92.5% (49/53) had complete
.......................................................................................................................................................................................
Table 1. Baseline Characteristics of Trial Participants, by Arm
Type Characteristic Category MþN( n ¼ 18) MþE( n ¼ 19) NþE( n ¼ 17)
Demographics Female 8 (44.4%) 9 (47.4%) 10 (58.8%)
Mean age (range) 29.1 (5–56) 28.1 (11–61) 29.1 (9–62)
Mean weight (SD) 49.2 (6 14.4) 50.0 (6 10.3) 51.4 (6 8.4)
Mean body mass index (SD) 19.0 (6 2.7) 18.6 (6 1.9) 19.5 (6 1.8)
Body mass index ,18.5 (thinness) 8 (44.4%) 7 (38.9%) 4 (23.5%)
Parasitology Trypanosomes in lymph nodes 9 (50.0%) 9 (47.4%) 9 (52.9%)
Trypanosomes in blood 14 (77.8%) 13 (68.4%) 16 (94.1%)
Trypanosomes in CSF 12 (66.7%) 17 (89.5%) 10 (58.8%)
Leukocyte count in CSF 6–20 cells/ll 4 (22.2%) 3 (15.8%) 6 (35.3%)
2–99 cells/ll 5 (27.8%) 4 (21.0%) 5 (29.4%)
 100 cells/ll 9 (50.0%) 1 (63.2%) 6 (35.3%)
Clinical characteristics Mean hemoglobin (SD), g/dl
a 10.8 (0.8) 11.2 (2.2) 11.7 (2.0)
Lymphadenopathy 9 (50.0%) 10 (52.6%) 10 (58.8%)
Headache 14 (77.8%) 17 (89.5%) 16 (94.1%)
Fever ( 37.5 8C) 4 (22.2%) 7 (36.8%) 6 (35.3%)
Pruritus 14 (77.8%) 17 (89.5%) 13 (76.5%)
Daytime somnolence 10 (55.6%) 13 (68.4%) 9 (52.9%)
Insomnia 4 (22.2%) 4 (21.0%) 0
History of seizures 0 (0%) 1 (5.3%) 0
Psychiatric signs 2 (11.1%) 1 (5.3%) 0
Impotence or amenorrhea 3 (16.7%) 1 (5.3%) 2 (11.8%)
Arthralgia/myalgia 11 (61.1%) 14 (73.7%) 13 (76.5%)
Percentages in parentheses indicate proportion of entire cohort.
aRespectively, n ¼ 14, 15, and 11.
doi:10.1371/journal.pctr.0010039.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Drug Combinations for Sleeping Sicknesstwo-year follow-up data. This satisfactory follow-up reinfor-
ces conﬁdence in the efﬁcacy ﬁndings.
In terms of safety the trends observed are very marked and
argue in favor of an advantage of the NþE combination as
well. With the MþE combination, intermediate results were
obtained in terms of both efﬁcacy and safety. Hematological
toxicity with eﬂornithine has been documented [2]. In our
data the two patients that developed severe neutropenia
point to a concerning issue that should be explored in further
studies, since it renders patients more vulnerable to
infections, including after leaving the hospital.
It is difﬁcult to draw comments on a possible inﬂuence of
ivermectin on toxicity, because only two patients had
received ivermectin prior to the study drugs and no distinct
toxicity was observed in comparison with the rest.
Generalizability and Limitations
Due to the small number of patients recruited we could not
perform the equivalence analysis designed in the protocol.
.......................................................................................................................................................................................
Table 2. Efficacy Outcome Per Treatment Arm
Analysis Arm Cured (n) Cure Rate (%) Relative Risk Exact 95% CI p-Value
a
Full intention-to-treat analysis
b (n ¼ 54) MþN( n ¼ 18) 8 44.4 — — —
MþE( n ¼ 19) 15 78.9 1.78 1.01–3.13 0.045
NþE( n ¼ 17) 16 94.1 2.12 1.25–3.60 0.003
Per-protocol analysis
c (n ¼ 53) MþN( n ¼ 18) 9 50.0 — — —
MþE( n ¼ 18) 15 83.3 1.67 1.00–2.76 0.075
NþE( n ¼ 17) 17 100.0 2.00 1.26–3.17 0.001
Sensitivity analysis, worst-case scenario
d (n ¼ 54) MþN( n ¼ 18) 8 44.4 — — —
MþE( n ¼ 19) 13 68.4 1.54 0.84–2.81 0.191
NþE( n ¼ 17) 16 94.1 2.12 1.25–3.60 0.003
aFisher’s exact test
bIncludes all patients randomized. All deaths during treatment or follow-up regarded as treatment failures, irrespective of the cause. For the partially followed up still alive (two
patients), the last observation was carried forward.
cExcludes one patient who was not treated. For the partially followed up (two moved away and two died later of unrelated causes), the last valid observation was carried forward.
dIncludes all patients randomized. Four patients that were partially followed up were regarded as treatment failures. All-cause mortality is regarded as failure.
doi:10.1371/journal.pctr.0010039.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3. Clinical and Biological Adverse Events during Hospitalization
Category Adverse Events MþN( n ¼ 18) MþE( n ¼ 18) NþE( n ¼ 17)
Death 410
Neurological Seizures (major) 4 (4) 2 (2) 4 (4)
Confusion (major) 3 (2) 0 (0) 1 (0)
Coma (major) 2 (2) 0 (0) 0 (0)
Tremors 0 1 0
Agitation 2 0 0
Dizziness 2 1 1
Visual disturbance 0 2 0
Ataxia (major) 1 (1) 0 (0) 0 (0)
Gastrointestinal Abdominal pain 5 8 7
Diarrhea (major) 3 (0) 8 (2) 4 (0)
Nausea/vomiting 1 4 1
Cardiovascular Arrythmia (major) 3 (1) 1 (0) 0 (0)
Hypertension (major) 2 (1) 5 (2) 3 (0)
Hematological Anemia
a 010
Leukopenia
b 011
Neutropenia
b (major) 0 (0) 1 (1) 3 (1)
Other Fever (major) 6 (1) 3 (0) 3 (0)
Headache (major) 6 (1) 4 (1) 1 (0)
Weight loss   5% (major) 5 (1) 1 (0) 4 (0)
Cough 1 0 0
Pruritus 1 2 1
Skin rash 1 0 0
Total of adverse events 52 46 34
Total of major events 18 9 5
Patients suffering major events 844
Total treatment interruptions 741
Treatment suspension 4 4 1
Treatment termination 3 0 0
‘‘Major’’ indicates grades 3 and 4 of the NCI Common Toxicity Criteria [13]; major weight loss:   20%.
an ¼ 37; respectively 12, 15 and 10.
bn¼ 36; respectively 12, 14 and 10.
doi:10.1371/journal.pctr.0010039.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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The results obtained must therefore be interpreted with
caution, and should not be regarded as deﬁnitive proof.
This study should be considered as an exploratory
endeavor that has the merit of pointing to a direction for
further studies, in particular the coadministration of nifurti-
mox and eﬂornithine.
The early termination of the trial, although very limiting
from a scientiﬁc standpoint, was in our view an ethical
obligation on account of the fatality rate in the MþN arm
(one in four).
Overall Evidence
In the face of the extremely restricted therapeutic options for
stage 2 sleeping sickness, the need to test drug combinations
is urgent [2]. However, research in this area is notoriously
lacking. Other than the studies cited above [10–12], the
authors are not aware of published clinical trials examining
stage 2 HAT treatment in the last ten years.
Despite the clear sample size limitations of this study, we
believe that the data are of crucial interest because of the
promising results in terms of efﬁcacy and safety of the NþE
combination, which was here evaluated for the ﬁrst time. The
NþE combination offers cost and feasibility advantages as
well.
Nifurtimox has direct trypanocidal action through oxida-
tive stress [14]. Eﬂornithine has trypanostatic effects that
cripple the parasite’s replication and defenses against the
host immune system; these effects include reduction of
trypanothione levels, which decreases the parasite’s ability
to resist oxidative stress [15]. These different modes of action
of the NþE combination should offer good efﬁcacy, and our
data appear consistent with this assumption.
A degree of protection against the emergence of drug
resistance would also be expected from the NþE combination,
as is the case for drug combinations already in use for other
parasitic, bacterial, and viral diseases. This combination
offers improved safety over melarsoprol, which causes acute
reactive encephalopathy; furthermore, because in the combi-
nation eﬂornithine is halved, the reduced number of IV
infusions would be expected to reduce the frequency of
iatrogenic phlebitis and soft-tissue bacterial infections that
result from excessive intravenous manipulation in hygiene-
poor settings [11]. Moreover, halving the eﬂornithine total
dose and administration time may reduce the myelosuppres-
sive effects [16] and possibly the gastrointestinal adverse
events [11] observed with longer regimens. Similarly, the
reduced dose and duration of nifurtimox may reduce the
frequency and severity of its toxic effects. Potential toxic
effects deriving from drug interaction, however, even with
reduced doses, need to be assessed in larger studies.
The use of the NþE combination assessed in our study may
reduce cost compared to the current eﬂornithine regimen,
since it halves costs related to the IV infusions, shortens
hospitalization time, and replaces half of the eﬂornithine—a
costly drug—with ten days of the less-expensive nifurtimox.
The feasibility of any HAT treatment regimen is of great
importance, since most treatment centers are located near
the foci of disease transmission, in remote areas where
logistical means and trained staff are scarce. This NþE
regimen, with 28 eﬂornithine infusions over 7 d instead of
56 infusions over 14 d, is a good step forward in this sense.
Following this trial, we organized a case-series study and
another clinical trial to continue evaluating the NþE
combination. We believe that this track merits further
exploration since it has the potential to signiﬁcantly improve
the fate of infected patients treated in stage 2, who remain
the majority of the sleeping sickness burden.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0010039.sd001 (40 KB DOC).
Trial Protocol
Found at doi:10.1371/journal.pctr.0010039.sd002 (138 KB DOC).
Alternative Language Abstract S1.
Translation of the Abstract into Spanish by Gerardo Priotto.
Found at doi:10.1371/journal.pctr.0010039.sd003 (28 KB DOC).
Alternative Language Abstract S2.
Translation of the Abstract into French by Gerardo Priotto.
Found at doi:10.1371/journal.pctr.0010039.sd004 (29 KB DOC).
Alternative Language Abstract S3.
Translation of the Abstract into Portuguese by Martine Guillerm.
Found at doi:10.1371/journal.pctr.0010039.sd005 (22 KB DOC).
ACKNOWLEDGMENTS
We thank the Ugandan Ministry of Health whose cooperation in
setting up the study was invaluable. We are indebted to the clinical
and laboratory ﬁeld team members, international and local, whose
hard work permitted this research to happen. The following
individuals participated in the protocol development, through a
scientiﬁc committee: Gae ¨lle Ollivier, Dominique Legros, Marc
Gastellu-Etchegorry, Thierry Ancelle, Philippe Bu ¨scher, Pierre
Cattand, Christophe Paquet, Christian Burri, Cyrus Bacchi, and
Dawson Mbulamberi. The following provided laboratory technical
advice: Laurence Bonte, Philippe Bu ¨scher, and Veerle Lejon. Advice
on statistical analysis was kindly provided by Loretxu Pinoges,
Catherine Com-Nougue ´, and Simon Cousens. We are indebted to
Dominique Legros and Philippe Guerin for their critical reading of
the manuscript. Thanks to Martine Guillerm for the Portuguese
translation of the abstract.
Author Contributions
GP participated in study design together with the Scientiﬁc
Committee, and coordinated the study. GP, FC and SG analyzed the
data. GP, CF, MB, FC, and PP wrote the paper. CF assisted Dr. Priotto
in setting up the study in the ﬁeld and was responsible for daily
monitoring and supervision of the study for the ﬁrst eight months,
including laboratory and clinical work. MB and OE were clinicians in
the ﬁeld who enrolled and managed patients in the study and ﬁlled in
case report forms and collected data. AL collected laboratory data
throughout the study period. SG provided critical manuscript
revisions. PP collected data from patient follow-ups.
REFERENCES
1. Pepin J, Milord F, Khonde AN, Niyonsenga T, Loko L, et al. (1995) Risk
factors for encephalopathy and mortality during melarsoprol treatment of
Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg
89: 92–97.
2. World Health Organization (1998) Control and surveillance of African
trypanosomiasis: Report of a WHO expert committee. WHO Technical
Report Series 881. Geneva: WHO. 120 pp.
3. Burri C, Keiser J (2001) Pharmacokinetic investigations in patients from
northern Angola refractory to melarsoprol treatment. Trop Med Int
Health 6: 412–420.
4. Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D (1999) Risk factors
for treatment failure after melarsoprol for Trypanosoma brucei gambiense
trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 93: 439–442.
5. Stanghellini A, Josenando T (2001) The situation of sleeping sickness in
Angola: A calamity. Trop Med Int Health 6: 330–334.
www.plosclinicaltrials.org December | 2006 | e39 0007
Drug Combinations for Sleeping Sickness6. Janssens PG, De Muynck A (1977) Clinical trials with ‘‘nifurtimox’’ in
African trypanosomiasis. Ann Soc Belg Med Trop 57: 475–480.
7. Moens F, De Wilde M, Ngato K (1984) [Clinical trial of nifurtimox in human
African trypanosomiasis]. Ann Soc Belg Med Trop 64: 37–43.
8. Pepin J, Milord F, Meurice F, Ethier L, Loko L, et al. (1992) High-dose
nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sick-
ness: An open trial in central Zaire. Trans R Soc Trop Med Hyg 86: 254–
256.
9. Van Nieuwenhove S (1992) Advances in sleeping sickness therapy. Ann Soc
Belg Med Trop 72: 39–51.
10. Burri C, Nkunku S, Merolle A, Smith T, Blum J, et al. (2000) Efﬁcacy of new,
concise schedule for melarsoprol in treatment of sleeping sickness caused
by Trypanosoma brucei gambiense: A randomised trial. Lancet 355: 1419–1425.
11. Pepin J, Khonde N, Maiso F, Doua F, Jaffar S, et al. (2000) Short-course
eﬂornithine in Gambian trypanosomiasis: A multicentre randomized
controlled trial. Bull World Health Organ 78: 1284–1295.
12. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C (2004) Efﬁcacy of 10-
day melarsoprol schedule 2 years after treatment for late-stage gambiense
sleeping sickness. Lancet 364: 789–790.
13. National Cancer Institute, Cancer Therapy Evaluation Program, National
Institutes of Health (1999) Common toxicity criteria, version 2.0. Available:
http://ctep.info.nih.gov. Accessed: 09 November 2006.
14. Eze MO (1991) Towards more efﬁcacious chemotherapy of trypanosomia-
sis: Combination of alpha-diﬂuoromethylornithine (DFMO) with reactive
oxygen generating drugs. Med Hypotheses 36: 246–249.
15. Fairlamb AH, Henderson GB, Bacchi CJ, Cerami A (1987) In vivo effects of
diﬂuoromethylornithine on trypanothione and polyamine levels in blood-
stream forms of Trypanosoma brucei. Mol Biochem Parasitol 24: 185–191.
16. Abeloff MD, Slavik M, Luk GD, Grifﬁn CA, Hermann J, et al. (1984) Phase I
trial and pharmacokinetic studies of alpha-diﬂuoromethylornithine—An
inhibitor of polyamine biosynthesis. J Clin Oncol 2: 124–130.
www.plosclinicaltrials.org December | 2006 | e39 0008
Drug Combinations for Sleeping Sickness